دورية أكاديمية
أعرض في EDS

Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years.

التفاصيل البيبلوغرافية
العنوان: Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years.
المؤلفون: Fragoso YD; Department of Neurology and MS Unit, Universidade Metropolitana de Santos, Santos, SP, Brazil. Electronic address: yara@bsnet.com.br., Alves-Leon SV; Department of Neurology and MS Unit, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Department of Neurology and MS Unit, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Barreira AA; Department of Neurology and MS Unit, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil., Callegaro D; Department of Neurology and MS Unit, Hospital das Clinicas, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Brito Ferreira ML; Department of Neurology and MS Unit, Hospital da Restauracao de Recife, Recife, PE, Brazil., Finkelsztejn A; Department of Neurology and MS Unit, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil., Gomes S; Department of Neurology and MS Unit, Hospital Beneficencia Portuguesa and Hospital Paulistano, Sao Paulo, SP, Brazil., Magno Goncalves MV; Department of Neurology and MS Unit, Hospital Regional Hans Dieter Schimidt, Joinville, SC, Brazil., Moraes Machado MI; Department of Neurology and MS Unit, Hospital da Restauracao de Recife, Recife, PE, Brazil., Marques VD; Department of Neurology and MS Unit, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil., Cunha Matta AP; Department of Neurology and MS Unit, Universidade Federal Fluminense, Niteroi, RJ, Brazil., Papais-Alvarenga RM; Department of Neurology and MS Unit, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Apostolos Pereira SL; Department of Neurology and MS Unit, Hospital das Clinicas, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Tauil CB; Department of Neurology and MS Unit, Hospital de Base do Distrito Federal, Brasilia, DF, Brazil.
المصدر: Pediatric neurology [Pediatr Neurol] 2015 Aug; Vol. 53 (2), pp. 166-8. Date of Electronic Publication: 2015 Apr 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Publishing Country of Publication: United States NLM ID: 8508183 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5150 (Electronic) Linking ISSN: 08878994 NLM ISO Abbreviation: Pediatr Neurol Subsets: MEDLINE
أسماء مطبوعة: Publication: New York Ny : Elsevier Science Publishing
Original Publication: Chippewa Falls, Wis. : Professional Publications, [c1985-
مواضيع طبية MeSH: Fingolimod Hydrochloride/*therapeutic use , Immunosuppressive Agents/*therapeutic use , Multiple Sclerosis/*drug therapy, Adolescent ; Brazil ; Child ; Child, Preschool ; Disability Evaluation ; Drug Prescriptions ; Female ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging ; Male
مستخلص: Background: There have been no clinical trials for approval of medications for treating multiple sclerosis in patients younger than age 18 years. All treatments are based on personal experience and data from open observational studies. Fingolimod is an oral drug for multiple sclerosis that has been shown to be efficient and safe in adults. The aim of our study is to describe patients with multiple sclerosis who started treatment with fingolimod before the age of 18 years.
Participants and Methods: Seventeen patients treated with fingolimod were identified in the Brazilian database of children and adolescents with multiple sclerosis. The average time of use of the drug was 8.6 months.
Results: Fingolimod showed a good safety and efficacy profile in these patients, all of whom had very active multiple sclerosis. After starting treatment with fingolimod, only one patient had a relapse and a new lesion on magnetic resonance imaging. The patients' degree of disability did not progress. No major adverse events were reported in relation to the first dose of the drug, nor in the short- and medium-term treatment. No patient has been followed for longer than 18 months, thus limiting long-term conclusions.
Conclusions: Off-label use of fingolimod in patients younger than age 18 years may be a good therapeutic option for multiple sclerosis control.
(Copyright © 2015 Elsevier Inc. All rights reserved.)
فهرسة مساهمة: Keywords: adolescents; children; fingolimod; multiple sclerosis
المشرفين على المادة: 0 (Immunosuppressive Agents)
G926EC510T (Fingolimod Hydrochloride)
تواريخ الأحداث: Date Created: 20150601 Date Completed: 20160422 Latest Revision: 20150803
رمز التحديث: 20240628
DOI: 10.1016/j.pediatrneurol.2015.03.024
PMID: 26026897
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-5150
DOI:10.1016/j.pediatrneurol.2015.03.024